Seeking Alpha

bio.bobby

bio.bobby
Send Message
View as an RSS Feed
View bio.bobby's Comments BY TICKER:
Latest  |  Highest rated
  • Orexigen: Poised To Grab A Large Part Of The Weight Loss Market [View article]
    "Orexigen Therapeutics (NASDAQ:OREX) investors were finally rewarded for their patience"

    Really? Did you not see that OREX went from $5.90 the day before approval to $5.14? Is a 13% loss in two days is your idea of a 'reward'?

    A 4% loss of weight will not equate into substantially better sales that a 3% loss. A third crappy drug in a small market is a turd.
    Sep 12 02:54 PM | 2 Likes Like |Link to Comment
  • Belviq Sales Trends - A Realistic Look [View article]
    Didn't your initial projection for Belviq (http://seekingalpha.co...) have the hockey stick starting a few months ago? How's that going?
    Sep 5 05:13 PM | 1 Like Like |Link to Comment
  • Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80% Return On The Short Side [View article]
    Looks like Wedbush less bullish on SNSS....http://bit.ly/1ll56EU
    Aug 29 12:02 PM | Likes Like |Link to Comment
  • Tekmira Pharmaceuticals: What Does The 'Animal Rule' Mean For Their Ebola Drug Development? [View article]
    Same "animal rule" hype that HEPH and CBLI used for radiation scares. This will repeat.
    Aug 22 12:33 PM | Likes Like |Link to Comment
  • Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80% Return On The Short Side [View article]
    http://bit.ly/1why25l

    When was the last time a SNSS insider BOUGHT a share? From link looks like a long time. I wonder why that is.....
    Aug 22 11:56 AM | 1 Like Like |Link to Comment
  • Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80% Return On The Short Side [View article]
    Wedbush with a BUY is a good sign to sell.

    http://bit.ly/YyDnyj, same rubes who had a $31 PT on ONTY before stimucrap data.
    Aug 22 11:52 AM | 1 Like Like |Link to Comment
  • Sunesis Pharmaceuticals, Inc. Offers A Moderate Risk 80% Return On The Short Side [View article]
    You left off that vosaroxin is a leftover from the 90s, and that SNSS had to increase the number of subjects in its trial and even then patients lived longer than expected.

    Sound familiar? People should recall this plot form such brilliant shorts as: ONTY, NVLT, ZIOP, GNVC.
    Aug 22 09:19 AM | 2 Likes Like |Link to Comment
  • DARA Q2 Shows Good Progress, Signs Of Upside [View article]
    How long has DARA been peddling KRN550? Didn't the last study end years ago?
    Aug 14 04:52 PM | 1 Like Like |Link to Comment
  • Targacept: Traveling The Rocky Road To Redemption [View article]
    You should stick to psychology and stay away from science. Hopefully no one lost money based on your terrible analysis.
    Jul 29 08:47 AM | Likes Like |Link to Comment
  • Inovio Data Not A Home Run, But Got Company In Great Scoring Position [View article]
    "Supplementary filing assured that the intent-to-treat analysis (data for all patients) also achieved statistical significance."

    Which end point achieved statistical significance? What was the magnitude of response compared to placebo? Why isn't INO disclosing this?
    Jul 25 03:09 PM | 1 Like Like |Link to Comment
  • Behind The Promotion Of Northwest Bio [View article]
    Excellent article!

    Regrettably, most retail investors will view this as "bashing" to their detriment.
    Jul 7 10:18 AM | 7 Likes Like |Link to Comment
  • The FDA Owes Us An Answer On Questcor's Acthar [View article]
    Citron's report was demonstrably incorrect: they used a non-USP method to measure Acthar activity. Had Citron showed that Acthar didn't match specification via the USP method QCOR would have an issue, but Citron did not. Was weak work on Citron's part.
    Jun 26 09:00 AM | Likes Like |Link to Comment
  • Galena: A Good Investment Gone Bad [View article]
    This is and has always been a scam.

    I hope Mark Ahn ends up in prison for this fraud.
    Mar 18 10:29 AM | 6 Likes Like |Link to Comment
  • Questcor Questions Pile Up Again [View article]
    The 'special sauce' ploy is disheartening and a cynical way to do business but, sadly, it also works in this context.

    Don't look to QCOR to develop Synacthen. I'll bet they drag their feet and never even submit an NDA.
    Mar 18 09:30 AM | Likes Like |Link to Comment
  • Questcor Questions Pile Up Again [View article]
    Problem is the release specification for Acthar is vassoporessin activity protein content. Citron could just as easily done this relevant test (it's described in exquisite detail in the USP), but choose not to.

    Also, what were the experimental conditions? This is critical in work like this, so why can't Citron release them? The story that they're trying to protect identity, and don't have a black marker to redact names, is absurd.
    Mar 17 08:21 AM | 1 Like Like |Link to Comment
COMMENTS STATS
522 Comments
479 Likes